Estrogens can signal through either estrogen receptor ␣ (ER␣) or ␤ (ER␤) to ameliorate experimental autoimmune encephalomyelitis (EAE), the most widely used mouse model of multiple sclerosis (MS). Cellular targets of estrogen-mediated neuroprotection are still being elucidated. Previously, we demonstrated that ER␣ on astrocytes, but not neurons, was critical for ER␣ ligand-mediated neuroprotection in EAE, including decreased T-cell and macrophage inflammation and decreased axonal loss. Here, we determined whether ER␤ on astrocytes or neurons could mediate neuroprotection in EAE, by selectively removing ER␤ from either of these cell types using Cre-loxP gene deletion. Our results demonstrated that, even though ER␤ ligand treatment was neuroprotective in EAE, this neuroprotection was not mediated through ER␤ on either astrocytes or neurons and did not involve a reduction in levels of CNS inflammation. Given the differential neuroprotective and anti-inflammatory effects mediated via ER␣ versus ER␤ on astrocytes, we looked for molecules within astrocytes that were affected by signaling through ER␣, but not ER␤. We found that ER␣ ligand treatment, but not ER␤ ligand treatment, decreased expression of the chemokines CCL2 and CCL7 by astrocytes in EAE. Together, our data show that neuroprotection in EAE mediated via ER␤ signaling does not require ER␤ on either astrocytes or neurons, whereas neuroprotection in EAE mediated via ER␣ signaling requires ER␣ on astrocytes and reduces astrocyte expression of proinflammatory chemokines. These findings reveal important cellular differences in the neuroprotective mechanisms of estrogen signaling through ER␣ and ER␤ in EAE.
Introduction
Estrogens are neuroprotective in numerous animal disease models of the CNS, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis (MS). This neuroprotection ranges from prevention of neuronal loss to proper maintenance of the mitochondria (Lee and McEwen, 2001; Wise, 2002; Brinton, 2008; Spence and Voskuhl, 2012) . Whereas therapeutic effects of estrogen treatment in experimental models of diseases have been shown, the cellular targets of estrogen treatment are not yet fully understood.
Experimental autoimmune encephalomyelitis (EAE) is the most widely used mouse model of MS (Gold, 2006; Croxford et al., 2011) . Similar to MS, EAE consists of CNS inflammation, demyelination, and axonal loss (Trapp and Nave, 2008) . Estrogen treatment exerts well-documented protective effects in EAE (Gold and Voskuhl, 2009; Spence and Voskuhl, 2012) . Previous studies showed that treatment with either estrogen receptor ␣ (ER␣) ligand or estrogen receptor ␤ (ER␤) ligand ameliorated EAE, as well as prevented demyelination and axonal loss (Morales, 2006; Tiwari-Woodruff et al., 2007; Crawford et al., 2010; Spence et al., 2011) . However, ER␣ ligand and ER␤ ligand effects in EAE exhibit important differences. Previous data showed that ER␣ ligand treatment decreased the amount of immune cell infiltration into the CNS, whereas ER␤ ligand treatment did not (Tiwari-Woodruff et al., 2007) . However, ER␤ ligand treatment was able to qualitatively affect CNS infiltration as well as promote remyelination (Crawford et al., 2009; . Together, these observations suggest that the differences between the two ER ligands are not only the result of different pharmacological effects on each receptor, but that each ligand may have different cellular targets.
Regarding cellular targets of estrogen treatments, previous work from our laboratories demonstrated that astrocytes, but not neurons, are the target of ER␣ ligand's protective effects during EAE (Spence et al., 2011). Here, we determined whether ER␤ ligand also ameliorated EAE through direct actions on astrocytes or neurons. To do so, we used a genetic loss-of-function strategy.
We selectively deleted ER␤ from astrocytes or neurons using a well-characterized Cre-loxP system for astrocyte conditional gene knock-out (astrocyte-CKO) in mice to remove ER␤ (astrocyte-CKO-ER␤ [aCKO-ER␤]) (Herrmann et al., 2008; Spence et al., 2011) and for neuronal conditional gene knock-out (neuronal-CKO) in mice to remove ER␤ (neuronal-CKO-ER␤) (ForssPetter et al., 1990; Kwon et al., 2006 ). Our findings demonstrate that ER␣ expression on astrocytes, but not ER␤ expression on astrocytes or neurons, is necessary for estrogen-mediated neuroprotection during EAE. Furthermore, treatment with ER␣ ligand, but not ER␤ ligand, decreased astrocytic levels of chemokines that contribute to CNS inflammation.
Materials and Methods
Animals. All mice were on a C57BL/6 background achieved by at least 10 generations of back crossing. Astrocyte-ER␣-CKO were generated by crossing mice of mGFAP-Cre line 73.12 (Herrmann et al., 2008) with mice carrying an ER␣ gene in which exon 3 was flanked by loxP sites (ER␣ flox/flox ) were the generous gift from Professor Pierre Chambon (Strasbourg) (Dupont et al., 2000) . Astrocyte-ER␤-CKO were generated by crossing mice of mGFAP-Cre line 73.12 (Herrmann et al., 2008) with mice carrying an ER␤ gene in which exon 3 was flanked by loxP sites (ER␤ flox/flox ) were the generous gift from Professor Pierre Chambon (Strasbourg) (Dupont et al., 2000) . Neuronal-ER␤-CKO were generated by crossing mice of rNSEII-Cre (Forss-Petter et al., 1990; Kwon et al., 2006) with mice carrying an ER␤ gene in which exon 3 was flanked by loxP sites (ER␤ flox/flox ) were the generous gift from Professor Pierre Chambon (Strasbourg) (Dupont et al., 2000) . Animals were maintained under standard conditions in a 12 h dark/light cycle with access to food and water ad libitum. All procedures were done in accordance to the guidelines of the National Institutes of Health and the Chancellor's Animal Research Committee of the University of California, Los Angeles Office for the Protection of Research Subjects.
Adoptive EAE and hormone manipulations. C57BL/6 donor animals were immunized subcutaneously with myelin oligodendrocyte glycoprotein, amino acids 35-55 (200 g/animal, American Peptides) emulsified in Complete Freund's Adjuvant, supplemented with Mycobacterium Tuberculosis H37Ra (200 g/animal, Difco Laboratories), over four sites drained by inguinal and auxiliary lymph nodes in a total volume of 0.1 ml/mouse. Immunized mice had lymph node cells cultured in 24-well plates at a concentration of 3 ϫ 10 6 cells/ml of complete RPMI medium. (Tiwari-Woodruff et al., 2007) . Animals were monitored daily for EAE signs based on a standard EAE 0 -5 scale scoring system: 0, healthy; 1, complete loss of tail tonicity; 2, loss of righting reflex; 3, partial paralysis; 4, complete paralysis of one or both hind limbs; and 5, moribund.
Histological preparation. Female mice were deeply anesthetized in isoflurane and perfused transcardially with ice-cold 1ϫ PBS for 20 -30 min, followed by 10% formalin for 10 -15 min. Spinal cords were dissected and submerged in 10% formalin overnight at 4°C, followed by 30% sucrose for 24 h. Spinal cords were cut in thirds and embedded in optimal cutting temperature compound (Tissue Tek) and frozen at Ϫ80°C; 40-m-thick free-floating spinal cord cross-sections were obtained with a microtome cryostat (model HM505E) at Ϫ20°C. Tissues were collected serially and stored in 0.1 M PBS with 1% sodium azide in 4°C until immunohistochemistry.
Immunohistochemistry. Before histological staining, 40-m-thick freefloating sections were thoroughly washed with 0.1 M PBS to remove residual sodium azide. For tissues to be treated with diaminobenzidine (DAB), sections were permeabilized with 0.5% Triton X-100 in 0.1 M TBS and 10% normal goat serum for 60 min at room temperature. The following primary antibodies were used: anti-CD3 at 1:2000 (BD Biosciences PharMingen), anti-neurofilament-NF200 at 1:750 dilutions (Sigma), anti-Iba-1 at 1:10,000 (Wako Chemicals), anti-GFAP at 1:40,000 (Dako), anti-NeuN at 1:250 (Sigma), anti-ER␤ at 1:5000 (Millipore), aquaporin 4 at 1:100 (Abcam), anti-MCP-1 (CCL2) at 1:200 (Torrey Pines Biolabs), CCL7 (Sigma) at 1:50, and anti-MBP at 1:750 (Sigma). Tissues were then washed three times for 10 min in 0.1 M TBS. Tissues were labeled with secondary antibodies conjugated to Cy5 or Cy3 (Vector Laboratories and Millipore Bioscience Research Reagents) for 1 h for NF-200, NeuN, MBP, CCL2, CCL5, CCL7, CCL8, aquaporin-4 (AQP4), and GFAP. Tissues were labeled with biotin secondary antibodies for CD3 and Iba-1, followed by ABC/DAB treatment (Vector Laboratories). Fluorescent sections were mounted on slides, allowed to semidry, and coverslipped in fluoromount G (Fisher Scientific). DAB sections were dried overnight and then dehydrated in 70%, 95%, and 100% ethanol, followed by 5 min of Citrasolve and coverslipped with Permount (Fisher Scientific). IgG-control experiments were performed for all primary antibodies, and only nonimmunoreactive tissues under these conditions were analyzed. Immunohistochemistry for ER␤ was followed directly as previously described (Giraud et al., 2010).
Quantification. To quantify immunohistochemical staining results, three dorsal column spinal cord cross-sections at the T1-T5 level from each mouse were captured under microscope at 10ϫ or 40ϫ magnification using the DP70 Image software and a DP70 camera (both from Olympus). All images in each experimental set were captured under the same light intensity and exposure limits. Image analysis was performed using ImageJ Software version 1.30 downloaded from the NIH website (http://rsb.info.nih.gov/ij). Three sections from each animal were then quantified to calculate the mean per animal. Immunohistochemical experiments were combined from three separate clinical trials. To control for variance, each immunohistochemical experiment was run as one large experiment with n ϭ 9 -12 per group. Each immunohistochemical experiment was repeated at least twice to confirm data. Myelinated axons were calculated by counting the number of NF200 ϩ axons in a 40ϫ image over the area of the captured tissue section that were fully enclosed by MBP. Axonal densities were calculated by counting the number of NF200 ϩ axons in a 40ϫ image over the area of the captured tissue section. Inflammatory infiltrates were quantified by counting the number of DAB-positive cells in the dorsal column of the thoracic spinal cord at 40ϫ under a light microscope. GFAP was calculated as percentage intensity or area, respectively, from the dorsal column. AQP4, CCL7, and CCL2 were measured as coexpression with GFAP in ImageJ, then divided over the total amount of GFAP in each section and presented as a percentage.
Microscopy. Stained sections were examined and photographed using a confocal microscope (Leica TCS-SP) or a fluorescence microscope (BX51WI; Olympus) equipped with Plan Fluor objectives connected to a camera (DP70, Olympus). Digital images were collected and analyzed using Leica confocal and DP70 camera software. Images were assembled using Adobe Photoshop (Adobe Systems) and Microsoft PowerPoint. DAB sections were examined at the light level at 40ϫ (Nikon Alphaphot-2 YS2).
Statistical analysis. Differences in EAE clinical scores were determined by repeated-measures one-way ANOVA. Immunohistochemical data were analyzed by one-way ANOVA. For these analyses, one-way ANOVA, Bonferroni post hoc analysis was performed on F-stat values, and significance was determined at the 95% confidence interval (Prism).
Results

ER␤ is specifically deleted from astrocytes in astrocyte-CKO-ER␤ mice and in neurons in neuronal CKO-ER␤ (nCKO-ER␤) mice
To target CKO-ER␣ and CKO-ER␤ to astrocytes, we used a mouse GFAP (mGFAP)-Cre line previously shown to target Cre activity selectively in astrocytes in the CNS (Herrmann et al., 2008) . This mGFAP-Cre line is able to target 98% of all astrocytes with no targeting of other cells in the CNS, such as oligodendrocytes, microglia, and neurons. We then crossed this mouse line with ER␣ or ER␤-loxP mice, in which exon 3 of ER␣ or ER␤ gene is floxed (Dupont et al., 2000) . To target CKO-ER␤ to neurons, we used a rat neuronal specific enolase II-Cre line previously shown to target Cre activity selectively in neurons in the CNS (Forss-Petter et al., 1990; Kwon et al., 2006) . We then crossed this mouse line with ER␤-loxP mice, in which exon 3 of ER␤ gene is floxed (Dupont et al., 2000) . To determine the efficacy of ER␤ CKO from astrocytes and neurons, we performed immunohistochemistry in WT, astrocyte-CKO-ER␣ (aCKO-ER␣), aCKO-ER␤, and nCKO-ER␤ mouse lines with EAE. Our results demonstrated that ER␤ was absent in astrocytes in the aCKO-ER␤ mouse line, whereas it was present in astrocytes of both the WT and aCKO-ER␣ mouse line (Fig. 1A) . Our results also demonstrated that ER␤ was absent in neurons in the nCKO-ER␤ mouse line, whereas it was present in astrocytes of both the WT and aCKO-ER␤ mouse line the (Fig. 1B) . Previous work confirmed that ER␣ was absent in astrocytes from the aCKO-ER␣ mouse line (Spence et al., 2011) .
ER␤ ligand does not act directly on astrocytes or neurons for clinical disease protection
To determine that astrocytes or neurons were the target of ER␤ ligand-mediated protection during EAE, we treated our aCKO-ER␤ mice and nCKO-ER␤ mice with ER␤ ligand during the effector phase of adoptive EAE (Kim et al., 1999) . WT mice with EAE treated with vehicle exhibited a level of clinical disease indistinguishable from aCKO-ER␤ mice or nCKO-ER␤ mice with EAE treated with vehicle, demonstrating that the removal of astrocyte or neuron ER␤ did not affect the clinical course of disease ( Fig. 1 D, E) . WT mice with EAE treated with ER␤ ligand showed significantly less clinical disease than WT mice with EAE treated with vehicle, confirming that ER␤ ligand treatment was able to ameliorate clinical disease (Tiwari-Woodruff et al., 2007; . Notably, ER␣ ligand treatment was not able to ameliorate clinical disease in the aCKO-ER␣ group, confirming that astrocytes are the target of ER␣ ligand for clinical disease protection ( Fig. 1C) (Spence et al., 2011) . In contrast, ER␤ ligand treatment was still able to ameliorate clinical disease in the aCKO-ER␤ and nCKO-ER␤ group, demonstrating that astrocytes and neurons are not the target of ER␤ ligand-mediated clinical disease protection ( Fig. 1 D, E ).
ER␤ ligand, unlike ER␣ ligand, does not act on astrocytes to prevent T-cell and macrophage inflammation in the CNS
Given the differential effect of ER␣ versus ER␤ ligand treatment on astrocytes, we used our two aCKO models to examine differences in the downstream effects that each ligand has on astrocytes in EAE. CNS inflammation, comprised principally of T cells and monocytes, are a hallmark of EAE (Tiwari-Woodruff et al., 2007; ). Thus, we used immunohistochemistry to quantify the levels of T cells and monocytes in ER ligand-treated EAE aCKO-ER␣ and aCKO-ER␤ mouse lines. Anti-CD3 antibody was used to detect T cells, whereas anti-Iba-1 antibody was used to detect Iba-1 ramified microglia and Iba-1 globoid macrophages as previously described Spence et al., 2011) . T cells were increased in all mice with EAE regardless of treatment or genotype compared with WT mice without EAE (Figs. 2A, 3 A, C) . WT mice with EAE treated with ER␣ ligand had significantly less T-cell inflammation compared with WT mice treated with vehicle, confirming the anti-inflammatory effects of ER␣ ligand on T-cell inflammation. Furthermore, the effect of ER␣ ligand on reducing T-cell inflammation was lost in the aCKO-ER␣ mice treated with ER␣ ligand, thereby demonstrating that ER␣ ligand acts upon astrocytes in vivo to decrease T-cell inflammation. In contrast, treatment with ER␤ ligand was not able to decrease T cells in any groups with EAE (Figs. 2A, 3C) . Furthermore, WT mice with EAE treated with ER␣ ligand had significantly less Iba-1 globoid macrophage inflammation com- pared with WT mice treated with vehicle, again confirming the anti-inflammatory effects of ER␣ ligand on macrophage inflammation. Furthermore, the effect of ER␣ ligand on reducing macrophages was lost in the aCKO-ER␣ mice treated with ER␣ ligand, thereby demonstrating that ER␣ ligand acts upon astrocytes in vivo to decrease levels of macrophages in the CNS in EAE (Spence et al., 2011) . In contrast, treatment with ER␤ ligand was unable to decrease macrophages in any groups with EAE (Figs. 2C, 3 B, D) . Interestingly, when Iba-1 ramified microglia were examined, there were no differences between groups (Fig. 2B, 3 B, D) . Given that EAE induced an increase in cells with the phenotype of phagocytic macrophages without any effect on cells with the phenotype of microglia suggests that the increase of CNS macrophages in EAE is most likely the result of peripheral infiltrating monocytes, as others have suggested (Ajami et al., 2011) .
ER␤ ligand, unlike ER␣ ligand, does not act on astrocytes to prevent demyelination, astrogliosis, and axonal loss in the CNS
We next examined classical neuropathology of EAE by quantifying differences in myelin, gliosis, and axons in the spinal cord (Morales, 2006; Tiwari-Woodruff et al., 2007; Spence et al., 2011) . To quantify myelin, we counted the number of axons using anti-neurofilament 200 (NF200) that were fully encompassed by a ring of MBP. Both ER␣ ligand and ER␤ ligand treatment of WT mice with EAE reduced demyelination compared with WT mice with EAE treated with vehicle, confirming the protective effect of both of these ligand on myelin loss (Tiwari-Woodruff et al., 2007; (Figs. 4, 5 A, D) . Interestingly, ER␤ ligand treatment was able to prevent demyelination in aCKO-ER␤ mice, suggesting that ER␤ ligand acts upon another cell other than astrocytes to protect against myelin loss. In contrast, ER␣ ligand treatment was not able to prevent demyelination in aCKO-ER␣ mice, suggesting that ER␣ ligand acts upon astrocytes in vivo to prevent myelin loss (Figs. 4, 5 A, D) . Axonal loss is known to correlate with clinical disease scores (Wujek et al., 2002) . Thus, we counted the number of axons using NF200. Both ER␣ ligand and ER␤ ligand treatment of WT mice with EAE prevented axonal loss compared with WT mice with EAE treated with vehicle, confirming the protective effect of both of these ligand on axonal loss (Tiwari-Woodruff et al., 2007; Spence et al., 2011) (Figs. 4B, 5 B, E) . Interestingly, ER␤ ligand treatment was able to prevent axonal loss in aCKO-ER␤ mice, suggesting that ER␤ ligand acts upon another cell other than astrocytes to protect against axonal loss. In contrast, ER␣ ligand treatment was not able to prevent axonal loss in aCKO-ER␣ mice, suggesting that ER␣ ligand acts upon astrocytes in vivo to prevent axonal loss (Figs. 4B, 5 B, E) . To quantify reactive astrogliosis, GFAP expression was assessed. WT mice with EAE treated with ER␣ ligand demonstrated a significant decrease in reactive gliosis compared with WT mice with EAE treated with vehicle. However, ER␣ ligand treatment was not able to decrease reactive astrogliosis in aCKO-ER␣ mice, suggesting that ER␣ ligand acts via ER␣ on astrocytes in vivo to decrease reactive astrogliosis (Figs. 4C, 5C ). In contrast, ER␤ ligand treatment had no effect on astrogliosis in any of the groups with EAE (Figs. 4C, 5F ), suggesting that ER␤ ligand, unlike ER␣ ligand, is not able to decrease reactive astrogliosis in the CNS.
ER␣ ligand treatment decreases CCL2 and CCL7, but not AQP4, expression in astrocytes in EAE
Because we had shown a distinction between ER␣ and ER␤ ligand's ability to affect T-cell and macrophage inflammation in the CNS, we used this selectivity to ascertain which small inflammatory molecules within astrocytes that ER␣ ligand, but not ER␤ ligand, might regulate. One molecule of interest was chemokine (C-C motif) ligand 2 (CCL2), previously known as monocyte chemotactic protein 1 (MCP-1). CCL2 is expressed in astrocytes and is known to correlate with a higher disease severity in various CNS injury models (Brambilla, 2005; Conductier et al., 2010; Carrillo-de Sauvage et al., 2012; Hamby et al., 2012) . In MS tissue, CCL2 is expressed in astrocytes surrounding active and chronic lesions (McManus et al., 1998; Simpson et al., 1998; Van Der Voorn et al., 2010) . In animal models, CCL2, and its receptor chemokine (C-C motif) receptor 2 (CCR2), KO mice are resistant to EAE (Izikson et al., 2000; Huang et al., 2001 ). This resistance could be the result of a decrease in macrophage recruitment into the CNS in these CCL2 KO mice (Huang et al., 2001) . Here, we demonstrated that CCL2 is expressed within reactive astrocytes and immune cells in the spinal cord of EAE mice (Fig. 6A-C) . Treatment with ER␣ ligand in vivo was able to reduce CCL2 expression in reactive astrocytes in WT mice compared with vehicle. Interestingly, ER␣ ligand treatment lost its ability to reduce CCL2 expression in reactive astrocytes in aCKO-ER␣ mice with EAE, thereby demonstrating that ER␣ ligand does indeed act on astrocytes in vivo to reduce CCL2 expression (Fig. 6D ). In contrast, in vivo treatment with ER␤ ligand was not able to reduce CCL2 expression in reactive astrocytes in any of the groups with EAE (Fig. 6E) . Together, this demonstrates the selectivity of ligation of ER␣, but not ER␤, on astrocytes in decreasing CCL2 expression during EAE.
Given our CCL2 data, we investigated other chemokines expressed by astrocytes that could be differentially affected by ER␣ versus ER␤ ligation during EAE. Our next molecule of interest was CCL7, previously known as MCP-3. CCL7 is expressed in astrocytes, and previous research showed that CCL7 expression directly correlated with CCL2 expression in astrocyte cultures (Thompson and Van Eldik, 2009; Hamby et al., 2012) . In MS postmortem tissue, CCL7 expression is expressed in astrocytes and surrounds MS lesions (McManus et al., 1998) . Furthermore, CCL7 expression has also been detected in the spinal cords of EAE animals (Adzemovic et al., 2012) . Therefore, we examined CCL7 expression within reactive astrocytes and saw a similar expression pattern to that of CCL2 in astrocytes (Fig. 7 A, B) . However, unlike CCL2, CCL7 expression was only found in reactive astrocytes and was not detected in infiltrating immune cells (Fig. 7C) . Treatment with ER␣ ligand in vivo was able to reduce CCL7 expression in reactive astrocytes in WT mice compared with vehicle. However, ER␣ ligand treatment lost its ability to reduce CCL7 expression in reactive astrocytes in aCKO-ER␣ mice with EAE, thereby demonstrating that ER␣ ligand does indeed act on astrocytes in vivo to reduce CCL7 expression (Fig. 7D) . In contrast, treatment with ER␤ ligand was not able to reduce CCL7 expression in reactive astrocytes in any of the groups with EAE (Fig. 7E) , suggesting that CCL7 expression in astrocytes can be decreased by ER␣, but not ER␤, ligand treatment in vivo. We also looked for expression of CCL5 and CCL8 but did not observe expression of these chemokines within astrocytes (data not shown).
Another possible small molecule expressed by astrocytes that could be responsible for the differential effects of ER␣ versus ER␤ ligand treatment on inflammation is AQP4. AQP4 is a water channel expressed by astrocytes and thought to play a critical role in the maintenance of the blood-brain barrier (Verkman et al., 2006 (Verkman et al., , 2011 Verkman, 2009 ). CNS diseases, such as spinal cord injury, are known to alter the expression of AQP4 (Kimura et al., 2010; Nesic et al., 2010). In EAE, AQP4 expression is upregulated and redistributed, whereas AQP4 KO mice are resistant to EAE Miyamoto et al., 2009; Wolburg-Buchholz et al., 2009) . Interestingly, treatment with estradiol had been previously shown to decrease AQP4 expression in astrocytes in vitro (Rutkowsky et al., 2011) . Thus, we quantified the expression of AQP4 in reactive astrocytes. Our results demonstrated that AQP4 is indeed expressed within reactive astrocytes in the spinal cord of EAE mice (Fig. 8 A, B) . However, AQP4 expression in astrocytes was increased in all mice with EAE regardless of genotype or treatment, suggesting that AQP4 was not altered with ER␣ or ER␤ ligand treatment in either WT or aCKO mice (Fig. 8C,D) . Together, these data revealed that the effects of ER␣ ligand treatment on astrocytes in vivo during EAE are selective in that they affect the expression of specific chemokines, such as CCL2 and CCL7, but not other immunomodulatory molecules, such as AQP4.
Discussion
Together, our findings reveal important differences in the cellular mechanisms that underlie the neuroprotective effects of estrogen signaling through either ER␣ or ER␤ in EAE. We show that neuroprotection in EAE-mediated via ER␤ signaling does not require ER␤ on astrocytes or neurons, whereas neuroprotection in EAE mediated via ER␣ signaling requires ER␣ on astrocytes and reduces astrocyte expression of chemokines that contribute to CNS inflammation. These findings have important implications for understanding the different possible means by which estrogens can ameliorate EAE and MS, and for strategies to exploit the potential of selective ER␣ or ER␤ ligands in treatment strategies for MS and other neuroinflammatory conditions.
Previous studies from various laboratories have shown that estrogens exert neuroprotective effects in EAE that consist of a decrease in clinical disease, a reduction of CNS inflammation, and a decrease in axonal loss (Elloso, 2005; Morales, 2006; Tiwari-Woodruff et al., 2007; Polanczyk et al., 2010; Spence et al., 2011) . Our findings here extend these observations by showing that estrogens can exert neuroprotection in EAE through markedly different cellular mechanisms when signaling through either ER␣ or ER␤. Consistent with previous studies, we found that both ER␣ ligand and ER␤ ligand decreased clinical disease, demyelination, and axonal loss in EAE and that ER␣ ligand, but not ER␤ ligand, significantly reduced inflammation (Morales, 2006; Tiwari-Woodruff et al., 2007; Crawford et al., 2009; Spence et al., 2011) . Notably, we found that the neuroprotective effects of ER␣ ligand were completely lost when ER␣ was selectively deleted from astrocytes, whereas selective deletion of ER␤ from astrocytes or neurons had no effect on the neuroprotective effects of ER␤ ligand. Thus, the neuroprotective effects of ER␣ ligand are mediated through astrocytes, whereas the neuroprotective effects of ER␤ ligand are mediated by some other cell type, perhaps by acting on microglia, dendritic cells, or oligodendrocytes (Crawford et al., 2010; Saijo et al., 2011) . In addition, we show that only signaling through ER␣, but not ER␤, decreased inflammation in EAE and that this effect required ER␣ on astrocytes and that ER␣ ligand reduced astrocyte levels of inflammatory chemokines, such as CCL2 and CCL7. Together, these findings demonstrate that markedly different cellular mechanisms underlie the neuroprotective effects of signaling through ER␣ or ER␤.
Implications for our results are not limited to the MS model (Morissette et al., 2008) . In animal models of ischemia, estradiol is known to reduce total infarct size. However, this protective effect is lost in a global ER␣ KO, but not in a global ER␤ KO, mice treated with estradiol, demonstrating that ER␣, but not ER␤, expression is necessary for estradiol neuroprotection during ischemia (Dubal et al., 2001; Dubal, 2006) . In another study, MPTP was given to WT as well as both global ER␣ KO and global ER␤ KO. In the absence of exogenous estrogen administration, the level of striatal dopamine loss was greater in global ER␣ KO com- pared with the WT and ER␤ KO, suggesting that ER␣ is more important than ER␤ in the MPTP model. However, when exogenous estradiol was given, both the ER␣ KO and ER␤ KO groups demonstrated a decrease in dopamine, suggesting that, whereas ER␣ is more important at physiological levels, ER␤ can play a role at therapeutic levels (Morissette et al., 2007) . Although the exact mechanisms of ER␣ versus ER␤ neuroprotection are unknown, researchers have started to uncover differential signaling events between ER␣ and ER␤ in the brain. In one such study, ER␣ ligand-treated mice showed an enhanced protection against an MPTP-induced decrease in striatal dopamine concentration compared with ER␤ ligand-treated mice. In addition, ER␣ ligand-treated mice demonstrated an enhanced protection against an MPTP-induced increase in IGF-1R levels compared with ER␤ ligand-treated mice, which showed no effect. Interestingly, independent of MPTP administration, ER␣ ligand increased the phosphorylation of neuroprotective kinases GSK3 and Akt at higher levels than ER␤ ligand (D'Astous et al., 2006) . In another example, in hippocampal primary neurons, ER␣ ligand was not as effective as ER␤ ligand in increasing the concentration of a glutamate-induced intracellular calcium rise. Furthermore, although both ligands were able to increase ERK phosphorylation in these neurons, the magnitude and timing of this increase were unique to each ligand (Zhao and Brinton, 2007) . In another hippocampal study, treatment with ER␤ ligand, but not ER␣ ligand, increased the synaptic proteins PSD-95, synaptophysin, and the AMPA-receptor subunit GluR1. This increase in synaptic proteins correlated with an improved performance in hippocampus-dependent memory tasks. These positive effects of ER␤ ligand treatment were lost in the global ER␤ KO model (Liu et al., 2008) . Together, these findings are all consistent with the notion that ER␣ or ER␤ signaling mediates neuroprotection via different cellular mechanisms, similar to our observations reported here.
Astrocytes have multiple functions and play complex roles in CNS function and disease (Sofroniew, 2005; Barres, 2008; Sofroniew and Vinters, 2009; Freeman, 2010) , including MS and EAE (Liedtke et al., 1998; Chastain et al., 2011) . Astrocytes have been shown to produce a multitude of proinflammatory and anti-inflammatory molecules that can alter CNS inflammation (Sofroniew and Vinters, 2009; Argaw et al., 2012; Hamby et al., 2012) . Given estrogens' ability to alter proinflammatory and anti-inflammatory molecules in astrocytes Cerciat et al., 2010; Giraud et al., 2010) ; and given our observed differences in effects on inflammation between ER␣ and ER␤ ligand-treated EAE mice, we investigated inflammatory molecules expressed by astrocytes that could be responsible for ER␣ ligand-mediated disease protection during EAE. Previous research showed that estrogen treatment in vivo correlated with a decrease in CCL2 expression in astrocytes during EAE, but whether estrogen acted directly or indirectly on astrocytes remained unknown. Further in vitro analysis, using astrocyte cultures, showed that this effect most likely occurred through ER␣ (Giraud et al., 2010) . Our results extend these results by demonstrating for the first time in vivo that CCL2 and CCL7 are decreased upon ligation of ER␣, but not ER␤, on astrocytes in EAE. Another astrocyte molecule reported to influence inflammation is AQP4. Previous in vivo data reported that estrogen was able to decrease AQP4 expression in an animal model of ischemia (Rutkowsky et al., 2011) . Interestingly, our in vivo data showed that neither ER␣ ligand nor ER␤ ligand significantly altered AQP4 expression on astrocytes. These differences could result from the fact that we used ER-specific ligands as opposed to estradiol, which can act on both nuclear and membrane ER␣ and ER␤. Alternatively, there may be disease-related differences because the previous reports used an animal model of ischemia, whereas we focused on an animal model of MS. To fully elucidate the role that astrocyte expression of CCL2 and CCL7 play in inflammation, studies using an astrocyte CKO of CCL2 (Ge et al., 2009) or CCL7 or both CCL2 and CCL7 are warranted.
The neuroprotective effects of estrogens, as well as their ligands that bind specifically to ER␣ or ER␤, are under investigation for potential therapeutic application in various clinical conditions, including MS. Our findings here demonstrate distinctly different cellular mechanisms for neuroprotective effects mediated via signaling through either ER␣ or ER␤ in EAE, the most widely used mouse model of MS. The anti-inflammatory and neuroprotective effects of ER␣ ligand are mediated via ER␣ on astrocytes, whereas the neuroprotective effects of ER␤ ligand occur without reducing inflammation and are independent of ER␤ on astrocytes or neurons and are therefore exerted via other cell types. These findings suggest that the effects of ER␣ ligand and ER␤ ligand treatment in MS are likely to vary and be influenced by the nature and phase of the disease, and that the different ligands may exhibit markedly different efficacies depending on the timing of their delivery. Such factors warrant further investigation.
